Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Total Liabilities: 2009-2025

Historic Total Liabilities for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Sep 2025 value amounting to $760.9 million.

  • UNITED THERAPEUTICS's Total Liabilities fell 25.56% to $760.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $760.9 million, marking a year-over-year decrease of 25.56%. This contributed to the annual value of $920.0 million for FY2024, which is 22.18% down from last year.
  • UNITED THERAPEUTICS's Total Liabilities amounted to $760.9 million in Q3 2025, which was up 3.61% from $734.4 million recorded in Q2 2025.
  • UNITED THERAPEUTICS's Total Liabilities' 5-year high stood at $1.3 billion during Q3 2023, with a 5-year trough of $734.4 million in Q2 2025.
  • For the 3-year period, UNITED THERAPEUTICS's Total Liabilities averaged around $1.0 billion, with its median value being $1.0 billion (2024).
  • Its Total Liabilities has fluctuated over the past 5 years, first rose by 10.97% in 2021, then dropped by 28.42% in 2025.
  • Over the past 5 years, UNITED THERAPEUTICS's Total Liabilities (Quarterly) stood at $1.2 billion in 2021, then rose by 3.11% to $1.2 billion in 2022, then fell by 5.26% to $1.2 billion in 2023, then dropped by 22.18% to $920.0 million in 2024, then declined by 25.56% to $760.9 million in 2025.
  • Its Total Liabilities stands at $760.9 million for Q3 2025, versus $734.4 million for Q2 2025 and $936.7 million for Q1 2025.